Mereo BioPharma Group PLC is a multi-asset biopharmaceutical company. It is focused on the acquisition, development, and commercialization of innovative therapeutics to improve outcomes for patients with rare and specialty diseases. The company portfolio consists of clinical-stage product candidates that include BPS-804 (setrusumab), AZD-9668 (alvelestat), BGS-649 (leflutrozole), OMP-313M32 (etigilimab), OMP-305B83 (navicixizumab) and BCT-197 (acumapimod).